Skip to main content

Timing of unsaturated fat intake improves insulin sensitivity via the gut microbiota-bile acid axis: a randomized controlled trial.

Nature communications2025-05-07PubMed
Total: 87.0Innovation: 9Impact: 0Rigor: 0Citation: 0

Summary

In a 12-week double-blind randomized feeding trial in prediabetes, consuming unsaturated fat at lunch (vs dinner) improved insulin sensitivity and reduced postprandial insulin and free saturated fatty acids without increasing postprandial glucose. Multi-omics analyses implicated gut microbiota and bile acid pathways in mediating these effects.

Key Findings

  • Lunch-timed unsaturated fat intake improved insulin sensitivity compared with dinner timing.
  • Postprandial insulin and serum free saturated fatty acids decreased with lunch-timed USFA, while postprandial glucose did not differ between groups.
  • Metagenomic and fecal metabolite profiles implicated gut microbiota–bile acid pathways in mediating metabolic benefits.

Clinical Implications

For patients with prediabetes or insulin resistance, prioritizing unsaturated fat at lunch may be a practical strategy to improve insulin sensitivity without affecting postprandial glucose, complementing macronutrient quality and energy targets.

Why It Matters

This trial advances chrononutrition by showing that meal timing of unsaturated fats can biologically modulate insulin sensitivity via the microbiome–bile acid axis. It provides mechanistic and translational evidence for timing-specific dietary prescriptions in metabolic disease.

Limitations

  • Modest sample size per arm (n=15) and 12-week duration limits long-term inference
  • Primary analyses limited to participants with complete fecal samples; generalizability needs confirmation

Future Directions

Test lunch-timed unsaturated fat within diabetes prevention programs at scale, assess durability and cardiometabolic outcomes, and identify microbial and bile acid signatures predictive of response.

Study Information

Study Type
RCT
Research Domain
Treatment
Evidence Level
I - High-quality randomized controlled trial with double-blind feeding design
Study Design
OTHER